Publikationen in Zusammenarbeit mit Forschern von University of Washington School of Medicine (20)

2024

  1. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide

    The Lancet Oncology, Vol. 24, Núm. 12, pp. e472-e518

  3. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

    eClinicalMedicine, Vol. 63

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

2020

  1. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis

    The Lancet Haematology, Vol. 7, Núm. 10, pp. e746-e755

  2. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 8, pp. 1940-1951

2018

  1. Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests

    Movement Disorders, Vol. 33, Núm. 11, pp. 1750-1759

  2. Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population

    Neurobiology of Aging, Vol. 70, pp. 325.e1-325.e5

  3. Target-enriched sequencing of chromosome 17q21.31 in sporadic tauopathies reveals no candidate variants

    Neurobiology of Aging, Vol. 66, pp. 177.e7-177.e10

2017

  1. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 389, Núm. 10064, pp. 67-76

  2. Intertumoral Heterogeneity within Medulloblastoma Subgroups

    Cancer Cell, Vol. 31, Núm. 6, pp. 737-754.e6

2016

  1. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Science Translational Medicine, Vol. 8, Núm. 341

2015

  1. Convergent genetic and expression data implicate immunity in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 11, Núm. 6, pp. 658-671

2014

  1. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease

    PLoS ONE, Vol. 9, Núm. 6

2013

  1. Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients

    Diabetologia, Vol. 56, Núm. 12, pp. 2743-2752

  2. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

    Nature Genetics, Vol. 45, Núm. 12, pp. 1452-1458

2012

  1. Commonfolate gene variant, MTHFR C677T, is associated with brain structure in two independent cohorts of people with mild cognitive impairment

    NeuroImage: Clinical, Vol. 1, Núm. 1, pp. 179-187

2011

  1. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism

    Circulation, Vol. 124, Núm. 25, pp. 2909-2919